Guidelines for abstract submission

Opens on:  22.11.2017
Submission mode:
 Abstract submission is only possible online at   Abstracts submitted by post, fax or email will NOT be accepted.
Presenting author registration: The presenting author must be registered. If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.
 Number of submissions:   One author can submit more than one abstract but there can only be ONE presenting author per abstract.
Language:  All abstracts must be submitted in English.
Originality of abstracts:  Work published elsewhere before November 2017 should NOT be submitted. However, previously published work can be resubmitted provided there are new methods and/or findings.
Disclosure of interests:  Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.
Regulatory approval:  The submitting author confirms that Institutional regulatory approval has been obtained.
Author consent:  The submitting author declares all authors have read and approved the submitted work. 

Abstract title: 

The title is limited to 120 characters excluding spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. ? should be written as alpha, ? as beta). Only use standard abbreviations and generic drug names in the title.  


 Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.

Abstract body:  


The abstract structure is laid out under the headings Background, Aims, Method, Results and Discussion.  Graphs, figures and photographs are NOT allowed. The length of the abstract is limited to 300 words. Only the abstract body counts towards this word limit. .  Only commonly accepted abbreviations should be used. Treatment groups or drug names should NOT be abbreviated. Less widely recognized abbreviations may be used if introduced on first usage.  Only approved and generic (non-proprietary) drug names should be used.  Do NOT enter the title, authors, or grant information into the abstract body submission field but include any references at the end of the abstract.

Selection and notification process: 

All submitted abstracts undergo a peer-review process by a pannel of reviewers. Accepted abstracts are selected for oral poster presentation or poster display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.  


Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by mid- November 2016. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.  

Author Registration: 

Presenting authors of accepted abstracts MUST register for the congress. If the entire registration fee is not paid by the deadline, the abstract will be automatically withdrawn and will NOT be presented or published. 

Presenting author changes: 

Changes to the presenting author for an abstract need to be requested using the appropriate form which can be found on the website.
Please note Conference 2017 will not be accepting late-breaking abstracts after 07.12.2017. All abstracts must be submitted during the regular submission period